Opioid REMS Could Be Linked To CME, FDA Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee panel members will weigh in on the value of common educational materials and the metrics for success.
You may also be interested in...
REMS For Opioids, LABAs May Be Driven By PBM "Feedback" Mechanism
Possible contract from FDA would involve assessing whether PBM distribution of safety information to physicians would change prescribing practices.
REMS For Opioids, LABAs May Be Driven By PBM "Feedback" Mechanism
Possible contract from FDA would involve assessing whether PBM distribution of safety information to physicians would change prescribing practices.
FDA's Opioid REMS Proposal Has Narrow Focus On Education
Faced with data gaps, inadequate metrics and the need to maintain access to therapies, FDA takes a narrow approach to addressing long-acting and extended-release opioid abuse and misuse in its proposed Risk Evaluation and Mitigation Strategy for the painkillers